InterCure announced that subsidiary Canndoc has entered into a strategic distribution agreement with Salomon, Levin, Elstein (S.L.E.,) which is owned by Teva Pharmaceuticals Industries. Under terms of the agreement, S.L.E. will distribute Canndoc’s GMP products to pharma clients, including hospitals, health maintenance organizations (HMOs) and all pharmacies in Israel, including pharmacy chains. In the future, as regulatory approvals allow, S.L.E. will provide logistics capability for exporting Canndoc’s products to countries that support regulations for the sale and distribution of cannabis products for medical use.
Follow Us
We are a one-stop shop Healthcare Advisory & Consulting boutique and we help businesses with funding, market access, business strategy, distribution.
Categories
Follow Us
Tags
AI
Alzheimer
antibodies
Biosimilar
Cancer
cardiovascular
cell therapy
CE Mark
clinical trial
Diagnostics
Digital Health
Drug Discovery
EpiVax'
FDA
FDA approval
funding
fundraising
HIV
Immunogenicity
Immunotherapies
INVO Bioscience
Licensing
M&A
medical device
microbiome
Neuro
next-gen sequencing
NGS
PathAI
pathology
Pepticom
peptides
pharma
PierianDx
RNA
robots
Shape Therapeutics
skin
software
SurgiMab
Therapeutics
therapies
USA
VIrology
Virus